Reproducibility of 99mTc-TRODAT-1 SPECT measurement of dopamine transporters in Parkinson's disease

Journal of Nuclear Medicine

Volumn 45, Issue 2, 2004, Pages 207-213

  Hwang, Wen J ^a   Yao, Wei J ^a   Wey, Shiaw P ^b   Ting, Gann ^c  

^a NATIONAL CHENG KUNG UNIVERSITY   (Taiwan)

^b CHANG GUNG UNIVERSITY   (Taiwan)

^c INSTITUTE OF NUCLEAR ENERGY RESEARCH   (Taiwan)

Author keywords

99mTc TRODAT 1; Dopamine transporter; Parkinson's disease; SPECT

Indexed keywords

[2 [[2 [[[3 (4 CHLOROPHENYL) 8 METHYL 8 AZABICYCLO[3.2.1]OCT 2 YL]METHYL](2 MERCAPTOETHYL)AMINO]ETHYL]AMINO]ETHANETHIOLATO]OXOTECHNETIUM TC 99M; DOPAMINE; DOPAMINE TRANSPORTER; CARRIER PROTEIN; DIAGNOSTIC AGENT; MEMBRANE PROTEIN; NERVE PROTEIN; RADIOPHARMACEUTICAL AGENT; TECHNETIUM COMPLEX; TECHNETIUM TC 99M TRODAT 1; TECHNETIUM TC 99M TRODAT-1; TROPANE DERIVATIVE;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONFIDENCE INTERVAL; CONTROLLED STUDY; FEMALE; HUMAN; LONGITUDINAL STUDY; MALE; NIGRONEOSTRIATAL SYSTEM; OUTCOME ASSESSMENT; PARKINSON DISEASE; PRIORITY JOURNAL; REPRODUCIBILITY; SCORING SYSTEM; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; BRAIN; CORPUS STRIATUM; METABOLISM; MIDDLE AGED; SCINTISCANNING;

BRAIN; CORPUS STRIATUM; DOPAMINE; DOPAMINE PLASMA MEMBRANE TRANSPORT PROTEINS; FEMALE; HUMANS; MALE; MEMBRANE GLYCOPROTEINS; MEMBRANE TRANSPORT PROTEINS; MIDDLE AGED; NERVE TISSUE PROTEINS; ORGANOTECHNETIUM COMPOUNDS; PARKINSON DISEASE; RADIOPHARMACEUTICALS; REPRODUCIBILITY OF RESULTS; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON; TROPANES;

EID: 1542609233     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. Fahn S. Parkinson disease, the effect of levodopa, and the ELLDOPA trial: earlier vs later L-DOPA. Arch Neurol. 1999;56:529-535.
2. Brooks DJ. Monitoring neuroprotection and restorative therapies in Parkinson's disease with PET. J Neural Transm Suppl. 2000;60:125-137.
3. 11C]-WIN 35,428 reveals marked declines in mild Parkinson's disease. Ann Neurol. 1993;34:423-431.
4. Lee CS, Samii A, Sossi V, et al. In vivo positron emission tomographic evidence for compensatory changes in presynaptic dopaminergic nerve terminals in Parkinson's disease. Ann Neurol. 2000;47:493-503.
5. Innis RB, Seibyl JP, Scanley BE, et al. Single photon emission computed tomographic imaging demonstrates loss of striatal dopamine transporters in Parkinson's disease. Proc Natl Acad Sci USA. 1993;90:11965-11969.
6. 123I]β-CIT striatal uptake correlates with symptom severity in Parkinson's disease. Ann Neurol. 1995;38:589-598.
7. 123I]FP-CIT SPECT shows a pronounced decline of striatal dopamine transporter labelling in early and advanced Parkinson's disease. J Neurol Neurosurg Psychiatry. 1997;62:133-140.
8. 123I]IPT and single-photon emission tomography. Eur J Nucl Med. 1997;24:415-421.
9. Fischman AJ, Bonab AA, Babich JW, et al. Rapid detection of Parkinson's disease by SPECT with altropane: a selective ligand for dopamine transporters. Synapse. 1998;29:128-141.
10. 99mTc]TRODAT-1 to dopamine transporters in patients with Parkinson's disease and in healthy volunteers. J Nucl Med. 2000;41:584-589.
11. 99mTc-TRODAT-1 imaging. J Nucl Med. 2001;42:1303-1308.
12. Whone AL, Rakshi JS, Watts RL, Brooks DJ. Two trials demonstrating disease-slowing effects of ropinirole, compared with L-dopa, in early Parkinson's disease [abstract]. Mov Disord. 2002;17(suppl 5):S85-S86.
13. Parkinson Study Group. Dopamine transporter brain imaging to assess the effects of pramipexole vs levodopa on Parkinson disease progression. JAMA. 2002;287:1653-1661.
14. Seibyl JP, Marek K, Sheff K, et al. Test/retest reproducibility of iodine-123-βCIT SPECT brain measurement of dopamine transporters in Parkinson's patients. J Nucl Med. 1997;38:1453-1459.
15. Seibyl JP, Laruelle M, van Dyck CH, et al. Reproducibility of iodine-123-β-CIT SPECT brain measurement of dopamine transporters. J Nucl Med. 1996;37:222-228.
16. 99mTc]TRODAT-1: a novel technetium-99m complex as a dopamine transporter imaging agent. Eur J Nucl Med. 1997;24:372-380.
17. Meegalla S, Plössl K, Kung MP, et al. Tc-99m-labeled tropanes as dopamine transporter imaging agents. Bioconjug Chem. 1996;7:421-429.
18. 99mTc]TRODAT-1: a dopamine transporter imaging agent. J Nucl Med. 1999;40:150-158.
19. Marek K, Jennings D, Seibyl J. Single-photon emission tomography and dopamine transporter imaging in Parkinson's disease. Adv Neurol. 2003;91:183-191.
20. Kung HF, Kim HJ, Kung MP, Meegalla SK, Plössl K, Lee HK. Imaging dopamine transporters in humans with technetium-99m TRODAT-1. Eur J Nucl Med. 1996;23:1527-1530.
21. Langston JW, Widner H, Goetz CG, et al. Core assessment program for intracerebral transplantations (CAPIT). Mov Disord. 1992;7:2-13.
22. 99mTc-TRODAT-1 [abstract]. Eur J Nucl Med. 1998;25(suppl):PS723.
23. 99mTc-TRODAT- 1 for dopamine transporter imaging [in Chinese, English abstract]. Ann Nucl Med Sci. 2001;14:223-230.
24. Chang LT. A method for attenuation correction in radionuclide computed tomography. IEEE Trans Nucl Sci. 1978;NS25:638-643.
25. Booij J, Habraken JB, Bergmans P, et al. Imaging of dopamine transporters with iodine-123-FP-CIT SPECT in healthy controls and patients with Parkinson's disease. J Nucl Med. 1998;39:1879-1884.
26. Seibyl JP, Marek K, Sheff K, et al. Iodine-123-β-CIT and iodine-123-FPCIT SPECT measurement of dopamine transporters in healthy subjects and Parkinson's patients. J Nucl Med. 1998;39:1500-1508.
27. Litvan I, Bhatia KP, Burn DJ, et al. Scientific issues committee report: task force appraisal of clinical diagnostic criteria for parkinsonian disorders. Mov Disord. 2003;18:467-486.
28. Vingerhoets FJ, Schulzer M, Ruth TJ, Holden JE, Snow BJ. Reproducibility and discriminating ability of fluorine-18-6-fluoro-L-dopa PET in Parkinson's disease. J Nucl Med. 1996;37:421-426.
29. Ishikawa T, Dhawan V, Kazumata K, et al. Comparative nigrostriatal dopaminergic imaging with iodine-123-βCIT-FP/SPECT and fluorine-18-FDOPA/ PET. J Nucl Med. 1996;37:1760-1765.
30. Parkinson Study Group. A multicenter assessment of dopamine transporter imaging with DOPASCAN/SPECT in parkinsonism. Neurology. 2000;55:1540-1547.
31. Brooks DJ. Imaging end points for monitoring neuroprotection in Parkinson's disease. Ann Neurol. 2003;53(suppl 3):S110-S119.
32. Marek K, Jennings D, Seibyl J. Dopamine agonists and Parkinson's disease progression: what can we learn from neuroimaging studies. Ann Neurol. 2003;53(suppl 3):S160-S169.
33. Stoessl AJ. Assessing the integrity of the dopamine system in Parkinson's disease: how best to do it? Mov Disord. 2001;16:804-806.